Omthera Pharmaceuticals files for a $75 million IPO

By Renaissance Capital,

Shutterstock photo

Omthera Pharmaceuticals, which is developing therapies for abnormalities in blood lipids, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Princeton, NJ-based company, which was founded in 2008, currently does not produce any revenue from its drug candidates. It plans to list on the NASDAQ under the symbol OMTH. BofA Merrill Lynch, Barclays and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by